glp-1 options for type 2 diabetes and obesity 2025 New Guidelines in What is the pipeline for

Novo's edge is the deeper clinical evidence behind semaglutide, particularly the cardiovascular data, and a three-month head start in prescriptions

Retatrutide is a weight loss medication currently in clinical trials

a direct causal link in humans has not been established, but patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should avoid this class of medicine [16] [17] Gallbladder disease rapid weight loss can increase the risk of gallstones and gallbladder inflammation [25] [26] Diabetic retinopathy rapid improvement in glycaemic control has been associated with worsening of diabetic retinopathy in people with pre-existing disease

Never share injection pens or devices with others, even if the needle has been changed, as this poses serious infection risks

How fast semaglutide works varies by individual, but most users notice appetite changes within the first two weeks and measurable weight loss by weeks four through eight